JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB253371

Lysosomal Galactocerebrosidase (GALC) Analysis Kit

Be the first to review this product! Submit a review

|

(2 Publications)

Lysosomal Galactocerebrosidase (GALC) Analysis Kit ab253371 uses a simple protocol to measure levels of lysosomal galactocerebrosidase in many cells types (adherent or non-adherent).

View Alternative Names

Galactocerebrosidase, GALCERase, Galactocerebroside beta-galactosidase, Galactosylceramidase, Galactosylceramide beta-galactosidase, GALC

1 Images
Fluorescent Cell Imaging - Lysosomal Galactocerebrosidase (GALC) Analysis Kit (AB253371)
  • Fluorescent Cell Imaging

Unknown

Fluorescent Cell Imaging - Lysosomal Galactocerebrosidase (GALC) Analysis Kit (AB253371)

Leukocytes derived from a healthy individual and from a Krabbe patient.

Fluorescence was recorded using a Tecan Infinite M200 Pro plate reader, blank readings were subtracted from samples and an average of 6 wells presented.

Key facts

Detection method

Fluorescent

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Enzyme activity assay": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

This kit offers an easy to use protocol for detecting levels of lysosomal galactocerebrosidase in many cells types (adherent or non-adherent).

Krabbe Disease is an autosomal recessive disorder that results from a deficiency in an enzyme known as galactocerebrosidase (galactosylceramidase, GALC). It is also called Globoid Cell Leukodystrophy. This name derives from the characteristic pathology of Krabbe Disease, where macrophages accumulate high levels of undegraded galactolipids as a result of the lack of GALC activity. These cells produce a characteristic morphology difference from healthy cells, and are often termed globoid cells. The Lysosomal Galactocerebrosidase Analysis kit offers an easy to use protocol for detecting levels of lysosomal galactocerebrosidase in many cells types (adherent or non-adherent) using a lysate method and a specific lipidic fluorogenic substrate.

This kit is sold by Marker Gene under product code M2774.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

What's included?

{ "values": { "1Unit": { "sellingSize": "1 Unit", "publicAssetCode":"ab253371-1Unit", "assetComponentDetails": [ { "size":"1 x 20 mL", "name":"Stop Buffer", "number":"AB253371-CMP04", "productcode":"" }, { "size":"1 x 20 mL", "name":"Lysis Buffer A", "number":"AB253371-CMP01", "productcode":"" }, { "size":"3 x 10 Vial", "name":"Substrate Reagent (Light sensitive)", "number":"AB253371-CMP05", "productcode":"" }, { "size":"1 x 5 mL", "name":"Reaction Buffer", "number":"AB253371-CMP03", "productcode":"" }, { "size":"1 x 20 mL", "name":"Lysis Buffer B", "number":"AB253371-CMP02", "productcode":"" } ] } } }

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
Multi
Appropriate long-term storage conditions
Multi
Storage information
Please refer to protocols

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

GALC also known as galactocerebrosidase or galactosylceramidase is an enzyme with a molecular mass of about 68 kDa. It functions mechanically by hydrolyzing galactosylceramide (galactocerebroside) into galactose and ceramide. GALC expresses widely in the brain and other nervous tissues particularly in the lysosomes of glial cells contributing to the breakdown of lipids. The efficient lysosomal degradation process performed by GALC is critical for maintaining cellular lipid homeostasis.
Biological function summary

GALC plays an important role in the metabolism of complex lipids. It functions not as part of a larger protein complex but rather as an independent enzyme acting on specific substrates like galactosylceramide. The enzyme's activity contributes to the transformation of lipids necessary for the proper structure and function of myelin in the central nervous system. By maintaining proper lipid levels GALC supports the integrity and stability of myelinated neurons.

Pathways

GALC is involved in the sphingolipid degradation pathway contributing to the catabolic process of sphingolipids. This pathway ensures the break down and recycling of sphingolipid components like ceramide which are essential for cell signaling and membrane integrity. Another relevant pathway is the lysosomal storage pathway where GALC's enzymatic function prevents the abnormal accumulation of galactosylceramide and related substrates. GALC activity has links to other lysosomal enzymes like arylsulfatase A which also participate in lipid metabolism within the lysosome.

GALC mutations and deficiencies lead to Krabbe disease a severe lysosomal storage disorder affecting the nervous system. This pathology results from the accumulation of psychosine a toxic metabolite causing widespread demyelination. Another related condition is globoid cell leukodystrophy associated with GALC dysfunction. Proteins like myelin-associated glycoprotein may interact indirectly with GALC through these disease processes as GALC's enzymatic activity affects myelin maintenance.

Product protocols

Target data

Hydrolyzes the galactose ester bonds of glycolipids such as galactosylceramide and galactosylsphingosine (PubMed : 8281145, PubMed : 8399327). Enzyme with very low activity responsible for the lysosomal catabolism of galactosylceramide, a major lipid in myelin, kidney and epithelial cells of small intestine and colon (PubMed : 8281145, PubMed : 8399327).
See full target information GALC

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Human gene therapy 33:499-517 PubMed35333110

2022

Efficacy and Safety of a Krabbe Disease Gene Therapy.

Applications

Unspecified application

Species

Unspecified reactive species

Juliette Hordeaux,Brianne A Jeffrey,Jinlong Jian,Gourav R Choudhury,Kristofer Michalson,Thomas W Mitchell,Elizabeth L Buza,Jessica Chichester,Cecilia Dyer,Jessica Bagel,Charles H Vite,Allison M Bradbury,James M Wilson

PloS one 11:e0156312 PubMed27228111

2016

Fluorogenic Substrates for Visualizing Acidic Organelle Enzyme Activities.

Applications

Unspecified application

Species

Unspecified reactive species

Fiona Karen Harlan,Jason Scott Lusk,Breanna Michelle Mohr,Anthony Peter Guzikowski,Robert Hardy Batchelor,Ying Jiang,John Joseph Naleway
View all publications
websiteProtocolBooklet
en

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com